Phase I clinical trial dose escalation - 4th cohort

Sep 09, 2015EVENTSHit 1379

The third cohort (100 mg) in dose escalation of Phase I clinical trial to evaluate the safety was finished successfully. The safety monitoring committee (SMC) recommended a dose escalation to the next level (140 mg). Three clinical sites in the USA started recruitment of patients with solid tumor for the forth cohort.

Next Collaboration with ANRT
Previous Announcement: 2nd annual general meeting of stockholders